公开(公告)号：US20230405040A1

公开(公告)日：2023-12-21

申请号：US18035198

申请日：2021-11-04

Applicant: AMGEN INC.

Inventor： Winnie SOHN ,  Zachary JONES ,  Helina KASSAHUN

IPC: A61K31/713 ,  C12N15/113 ,  A61K47/54 ,  A61K9/00 ,  A61P3/06

CPC classification number: A61K31/713 ,  C12N15/113 ,  A61K47/549 ,  A61K9/0012 ,  A61P3/06

Abstract: The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles. In particular, the present invention relates to methods for reducing serum Lp(a) levels and reducing the risk of cardiovascular events in patients with elevated levels of Lp(a) comprising administering an LPA-targeted RNAi construct according to specific dosage regimens. Pharmaceutical compositions comprising the LPA-targeted RNAi constructs for use in the methods are also disclosed.